At some point or another, we all come in contact with someone who has been adversely affected by cancer. With so many people being diagnosed with this awful disease, research dedicated to finding a cure has been at the forefront of medicine for years, and according to a new report by Frost & Sullivan, there is a new revelation in pre-testing to help improve the early detection and prevention of cancer.
According to the findings, Western European In Vitro Cancer Diagnostics Market, the cancer research/testing market has earned $736 million in 2011, with that number expected to rise over $1.5 billion by the end of the decade. The study also covers a new baseline of targeted treatment and testing, including immunoassay, immunohistochemistry, nucleic acid testing (NAT), clinical chemistry and other diagnostic methods. “The projected launch of new NAT products for cancer diagnosis will result in high growth rates and revenue generation in this segment,” said Divyaa Ravishankar, Frost & Sullivan Senior Research Analyst. “NAT products have the ability to determine the predisposition of the disease condition. They address the need for diagnostic tests that aid in the early detection and prevention of cancer.”
Most cancers are curable if they are caught within stage one, and with the growing number of patients being diagnosed with a formidable cure, early detection and prevention is vital. Current diagnostics are done with blood, urine or genetic tests, but the new form of testing will be targeted treatments allowing physicians to better track the progress of the disease. This will also help the patients get treated with the appropriate drugs to effectively fight the disease.
“On the one hand, efforts will have to be made to facilitate the integration of novel NAT technologies with existing laboratory systems,” advises Divyaa Ravishankar. “On the other hand, the development of innovative and more accurate tests, paralleled by initiatives at improving patient awareness about these new options, could create a ‘pull’ effect from patients, which could negate the increasing bargaining power of the centralized lab.”
Edited by Ashley Caputo